Biography
Interests
Hanqing Ye
Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester & Beyond Biotech, LLC. Shrewsbury, USA
*Correspondence to: Dr. Hanqing Ye, Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester & Beyond Biotech, LLC. Shrewsbury, USA.
Copyright © 2020 Dr. Hanqing Ye. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The application of recombinant DNA technologies in human gene therapy was firstly raised several decades ago, with science advancement, the utilization of genetically modified techniques offered vast therapeutic benefits and potential to these patients with severe genetic diseases, such as muscular dystrophy, B-cell acute lymphoblastic leukemia, cystic fibrosis, etc. Here, the article reviews the history and progress of gene therapy for scientific researches and clinical practices, the strategies of gene therapy design, gene delivery approaches, and state-of-the-art genome editing techniques, CRISPR-Cas9, et al. Although multiple gene therapy products were successively approved by FDA to use in patients, the challenges of gene therapy in the clinical practice are still remaining. The ethical and safety issues of gene therapy is still a consideration in the clinical application, as a consequence, the long-term intervention of germline gene therapy need to be investigated and valuated properly before medical application. The common bottlenecks in gene therapy are still focusing on the level of gene delivery, and both nonviral and viral vector delivery approaches keep limitation in the clinical application and need to be further improved.
Introduction
Currently, about 6000 known human inherited diseases were found (Database from NIH National Human
Genome Research Institute). These genetic diseases are caused by mutations or incorrect sequences in the
normal form of the genes. Gene therapy is a technique to replace defective gene that causes a disease in
an individual cells or tissues with a corrected gene, such as some severe hereditary diseases or cancer, etc.
Gene therapy are also used for treatment of some lethal diseases through over-expressing functional gene,
inactivating/knock-out a mutated gene, or regulating gene expression which is not functioning properly.
Human Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder, researches show mainly
point mutations, deletion, and duplication in the DMD gene cause prematurely truncated, dysfunctional
dystrophins, a protein important for maintaining the stability of muscle-fiber membranes [1]. Most recently,
Gene therapy with CRISPR/Cas9 system was used to restore the expression of the dystrophin gene in
cells carrying dystrophin mutations that cause DMD. Researchers design single or multiplexed sgRNAs to
restore the dystrophin reading frame by targeting the mutational hotspot at exons 45-55 and introducing
shifts within exons or deleting one or more exons. As a result, human dystrophin expression is restored in
vitro and in vivo [2]. Approximately 70 percent of the mutations in cystic fibrosis patients correspond to
a specific deletion of three base pairs, which results in the loss of a phenylalanine residue at amino acid
position 508 of the putative product of the cystic fibrosis gene [3]. Although clearance of viral vectors by
immunal defense in lung airway sets up barriers of efficient gene delivery and expression of the therapeutic
transgene, repeated nebulisation of nonviral CFTR gene therapy in patients with cystic fibrosis are in the
clinical trails, it shows repeated administration of nonviral CFTR gene therapy holds potential for the
further step along the path of translational cystic fibrosis gene therapy [4].
History and Progress of Gene Therapy
In past about 3 decades, a number of diseases have been studied or are ongoing with gene therapy, such
as severe combined immuno-deficiencies (SCID), Hemophilia, Leber Congenital Amaurosis, Parkinson’s
disease, muscle dystrophy, cystic fibrosis, sickle cell anemia, cancer and HIV, et al. In 1990s, a clinical trail
of gene therapy was initialed with retroviral-mediated the adenosine deaminase (ADA) gene transfer into
the T cells of two children with severe combined immunodeficiency (ADA-SCID), after 4 years, it showed
ADA gene expression in T cells persisted [5]. Later, gene therapy with hematopoietic stem cells, bone
marrow and peripheral blood lymphocytes as vectors were used to deliver genes for correcting ADA-SCID
hereditary diseases, which indicated safety and the efficacy of gene transfer [6,7]. Also, sickle cell disease
(SCD) is successfully treated in mice with lentiviral-mediated gene therapy [8]. Subsequently, a tremendous
amount of scientific researches related to gene therapy has been conducted to increase the understanding of
the basic biology of the diseases, various gene therapy strategies and technologies were developed to treat
diseases, also a series of guidelines and database were made to assist, monitor and assess the ethnic and safety
issues of gene therapy by FDA and NIH (Guideline: Points to Consider in Human Somatic Cells Therapy
and Gene Therapy, etc.; Database: ClinicalTrails.gov). Recently, gene therapy for some of lethal diseases has
resulted into the successful outcomes in several clinical trails. The European medicines Agency approved
the treatment of adult familial lipoprotein lipase deficiency patients with gene therapy medicine (Glybera).
Subsequently, gene therapy products were successively approved to use in several different countries.
In 2003, it was approved to treat head and neck squamous cell carcinoma with gene therapy product (Gendicine) by the State Food and Drug Administration of China. In 2007, oncolytic adenovirus for treatment of late-stage refractory nasopharyngeal cancer and gamma-retrovirus vector expressing cytocidal cyclin G1 was approved by Philippine FDA. In 2013, a gene therapy product, plasmid vector expressing Vascular Endothelial Growth Factor gene was approved by Russian Ministry of Healthcare and Social Development to treat for peripheral arterial disease. In 2017, The FDA in Unite State approved the first three gene therapy products, CAR T-cell therapy (Kymriah) for treatment of certain B-cell acute lymphoblastic leukemia (ALL), the GALGT2 gene therapy program for treatment of DMD with dystrophin gene mutation, and AAV virus mediated gene therapy (Luxturna/voretigene neparvovec) for treatment of biallelic RPE65 mutation-associated retinal dystrophy. Especially, it is the first time that FDA approve AAV mediated gene therapy, compared with other viral vectors, the advantage of AAV as a safe gene therapy vehicle makes it to be feasible for clinical application. Furthermore, FDA announced 10-20 gene therapy drugs would be approved in one year by 2025. The most recently, the innovation and scientific advancement of the CRISPRCas9 mediated genome editing offers new possibilities for treatment of diseases that might be challenging or impossible to address with gene transfer technologies.
Strategies of Gene Therapy
According to the variant mechanisms of numerous genetic disorders, researchers developed versatile strategies
of gene therapy, which can be classified as four types of strategies.
Although it is difficult to know the side effects of over-expression of a functional gene to treat a disease,
researchers were trying to over-express some existing genes due to their lack or dysfunction in diseases. In
rat models of stroke and epilepsy, gene therapy of over-expressing hsp 72 with defective herpes simplex virus
vectors improved neuron survival against focal cerebral ischemia and excitotoxin-induced seizures [9]. Also,
over-expression of VEGF165 with recombinant Sendai virus (SeV) demonstrated the possible therapeutic
treatment by delicate regulation of low VEGF165 expression in individuals with critical limb ischemia in
murine model [10].
Development of Homologous recombination based knockout and knock-in technology make it possible
to study the detail function of almost any genes. Combination of homologous recombination-based gene
targeting and ES cells, numerous gene function and disease mechanisms were uncovered in past several
decades. A number of researchers raised or developed different strategies for homologous recombinationbased
gene therapy. Sickle cell disease (SCD) can be corrected by homologous recombination with embryonic
stem cells in mouse model [11]. Combination of nuclear transplantation and homologous recombination,
it demonstrated immune-deficient Rag2-/- mouse can be repaired and restored normal function [12], etc.
However, the low frequency of homologous recombination in mammalian cells and complicated technological
programs limit its application for somatic gene therapy in human, also its safety and ethical issues keep the
obstacles for its clinical applications on germline gene therapy.
Although siRNA, miRNA and shRNA have different molecular mechanisms and characterizations, all of
them are working on the RNA level to regulate the RNA expression of the specific gene. RNA interefence
(RNAi) was first experimentally documented in 1998 in Caenorhabditis elegans by Fire A, et al. [13].
Based on RNAi acting mechanism and principle, researchers designed synthetic small interfering RNA
(siRNA) to regulate gene expression which can treat a wide range of diseases as therapeutic agents. siRNA
is generally 21 to 25 bp in length which is designed to be homology with the specific mRNA sequences to
knock-down its expression. Soutschek J, et al. [14] demonstrated chemically modified siRNA can silence
an endogenous gene encoding Apopipoprotein B (ApoB) after intravenous injection which reduced total
cholesterol level in the liver of mice. Short hairpin RNA (shRNA) are designed as sense and antisense
sequences connected by a loop of unpaired nucleotides by synthesis in vitro or carry into cells with plasmid
vectors which can produce functional siRNA by Dicer process in the cytoplasm. Koornneef A, et al. [15]
showed knockdown of ApoB expression with AAV mediated shRNA reduce serum total cholesterol and
low-density lipoprotein cholesterol (LDL-C) levels in murine liver. miRNA are small (19-24 nt) non-coding
endogenous RNA molecular exist in body which functions as negative regulators of coding gene mRNA
expression by cleavage of specific gene mRNA or repressing gene translation. Usually miRNA affects genes
responsible for cell proliferation, differentiation and apoptosis which may function as oncogenes or tumor
suppressors. Numerous researches show miRNA may serve as a promising target for anti-cancer therapies.
As potential therapeutic agents or targets, researchers can design artificial miRNA or miRNA tough decoys
(TuDs) to enhance or inhibit specific miRNA expression, which can apply for these diseases caused by
miRNA deregulation [16,17].
CRISPR/Cas system was discovered in bacteria as their adaptive immune response mechanisms against
foreign DNA. Later, researchers reconstitute type II CRISPR-Cas9 system with a single guide RNA
(sgRNA, the dual tracrRNA:crRNA engineered with complementary sequence of target gene) which
functions like a global positioning system (GPS) to bring the endonuclease Cas9 protein into the targeted
gene loci to create double strain break (DBS) on each strand of a DNA target site next to a PAM sequence,
by this way, the targeted gene either can be silenced by creation of mutations or precisely perform error prone
non homologue end joint (NHEJ). CRISPR/Cas9 mediated genome editing corrected the dystrophin gene
(Dmd) mutation in a mdx mice model, which produced genetically mosaic animals containing 2 to 100%
correction of the Dmd gene and greatly contribute to regenerating muscle [18]. Also, AAV-mediated local
or systemic delivery of CRISPR/Cas9 endonucleases restored the Dmd reading frame, as a consequence,
which partially recovered muscle functional deficiencies and generated a pool of endogenously corrected
myogenic precursors in mdx mouse muscle [19]. Currently, uncover of crystal structure/domain architecture
and understanding of subunit function of CRISPR/Cas9 allow researchers to design different variants of
Cas9 systems for diverse purposes by modification of Cas9 and PAM sequences [20]. Cas9 that lacked
nuclease activity (dCas9) fusing a transcriptional activation domain enable the CRISPR/Cas9 system to
transcriptionally activate target genes within the native chromosomal context [21]. An Aspartate-to-Alanine
(D10A) point mutation in the Ruvc catalytic domain of Cas9 nuclease (Cas9n) allows to nick rather than
cleave DNA to yield single-strand breaks [22]. In addition, use of truncated gRNAs can reduce off-target effects by 5000-fold or more [23]. In summary, Combination of DNA cleaving mechanism and the capacity
for multiplexed target recognition in CRISPR/Cas9 system, it is feasible to develop the cost-effective and
easy-to-use technology for precisely and efficiently targeting, editing, modifying genomic loci in a wide
array of cells and organisms.
Methods of Gene Delivery with Gene Therapy
The success of gene therapy is greatly dependent on the DNA delivery into target cells. In past several
decades, a number of DNA delivery methods are developed for gene therapy, including in nonviral and viral
gene vectors delivery.
Vectors for gene therapy can be delivered into target cells or tissues with physical methods, such as, needle
injection, electroporation, gene gun, ultrasound, hydrodynamic pressure and nanoparticles. In physical
methods, the simplest and most safety way for administration of DNA is needle injection of naked DNA
into target tissues or blood vessel. It is well known that nonviral gene delivery produces less immune response
than viral gene delivery. However, the expression level and the area after injection of naked DNA are generally
limited due to the rapid degradation by nucleases and clearance by the phagocyte system. As a consequence, it
may need highly volume of DNA administration with nonviral gene delivery [24]. To improve the expression
level of gene therapy vectors, various physical delivery methods have been developed. Electroporation is used
for enhancing the ability of DNA permeation into cell membrane and uptake into cells after injection of
naked DNA. Although electroporation can improve gene vector delivery and expression efficiency in various
tissues, the complicated electroporation programs and parameters need intense and high professional labors
to manipulate and optimize with the special medical devices [25]. Gene gun also can accelerate gene vectors
delivery into tissues or cells by shooting DNA coated gold particles into the cells with high pressure gas.
By this way, it allows DNA directly to penetrate through the cell membrane into the cytoplasm and the
nucleus. Skin is one of the ideal targets to manipulate DNA transfer with gene gun [26,27]. Ultrasound
employs ultrasonic wave to form short-lived (a few seconds) pores in plasma membrane which increases the
DNA permeability into cell membrane after injection of naked DNA. Currently this technique is used for
enhancing gene vector delivery to vascular cells, muscle and fetal mouse [28-30]. Hydrodynamic injection is
simple and highly efficient delivery DNA into internal organs via injection of large volume of naked DNA
solution with high speed into tail or other tissues vein, such as liver and limb muscles, et al. This simple
and high efficient gene delivery both work well in small rodent and large research animal models, which
will enable many gene therapy application in clinic [31,32]. Also gene vectors can be delivered into target
cells mediated by some chemical carriers, such as cationic lipid, peptide and cationic polymer, which can
form chemical-DNA complex to enhance gene expression via protection of DNA degradation or control
of DNA release in specific cell types or cell layers [33]. Currently, this technology is still optimized for the
researches and applications in the gene therapy field. Recently, it reported common cationic lipid nucleic
acid transfection reagents also can potently deliver protein which used for protein-based genome editing in
vitro and in vivo [34]. Due to the development of nano technology, a number of nanoparticles are optimized
and used for the gene delivery based on the different chemical carriers, such as polymeric nanoparticles, lipid
nanoparticles, magnetic nanoparticles, mesoporous silica nanoparticles, etc. According to the reports, these nanoparticles display several desirable characterizations including low toxicity, well controlled and high
gene delivery efficiency and multi-functionalities, etc [35-38].
Viral vector gene delivery use virus as vectors to deliver the target gene into cells or tissues to replace or
modify the defective gene, currently main viral vectors for gene therapy are adenovirus, retrovirus, lentivirus,
herpes simplex virus (HSV), and adeno-associated virus (AAV). Although some reports pointed out the
risk of safety issues due to the host immune response to the viral vector system [39,40], numerous research
reports and clinical practices have proved to be the most efficient methods of DNA transfer into host cells or
tissues with viral vectors. A number of viral vector mediated gene therapy researches demonstrate these viral
vector systems have unique advantages and limitations. Adenoviral vectors can efficiently deliver vectors
to both dividing and non-dividing cell types with wide tissue tropisms, but immune clearance of infected
cells often limits gene expression in vivo, also transient expression characterization make it not be good
for treatment of genetic diseases [41]. In 1999, treatment of genetic disease, an inherited enzyme (OTC)
deficiency, with adenovirus mediated gene therapy resulted into death of the patient, which speculated the
cause of death is toxicity of high titer adenovirus and highly immunogenic [42]. Retroviral and lentiviral
vector systems offer the advantages of large packaging capacity for gene delivery with cell and tissue specific
tropism, also which can long-term express the target gene due to integrating into the genome of the infected
cell [43]. However, both of retroviral and lentiviral vectors have risks to activate oncogenes to form tumor
due to its insertional mutagenesis [44-46]. Although retroviral gene therapy cases are overall quite successful,
a leukemia-like illness was developed in a SCID disease (T cells deficiency) treated with retroviral vector
[47]. To harness the risk of oncogenicity, researchers developed integration-deficient lentiviral vectors with
sustained and efficient transgene expression in vivo, which greatly reduces the risk of insertional mutagenesis
[48]. HSV virus can deliver large amounts of exogenous DNA, a phase I/II clinical study of gene therapy
based on retrovirus-mediated gene transfer of HSV type 1 thymidine kinase (HSV-1 TK) showed significant
therapeutic responses for treatment of recurrent glioblastoma [49], however, cytotoxicity and maintenance
of transgene expression remain as obstacles [50]. AAV virus can infect many non-dividing and dividing cell
types for long-term gene expression without insertional mutagenesis, which makes AAV to be employed
in gene therapy as a comparative safe and effective vector. Epidemiological studies have showed that 85%
of healthy women are seropositive for AAV, which suggests AAV might have evolved an ideal relationship
with its human host [51]. However, as an adverse effect, the presence of neutralizing antibodies (NAbs) after
natural AAV infections inhibits their transfection efficiency in re-exposed subjects, which might affect AAV
clinical application in the natural AAV infected population [52,53]. As disadvantages, engineered AAV has
a limited DNA packaging capacity, which only can maximum pack 4.7~4.9kb DNA, also diversity of AAV
serotypes and tropisms pose barriers to the universal application of AAV in gene therapy [54].
Types of Gene Therapy
Although Germline gene transfer or modification have widely researched in numerous genes in animal
models, however, germline gene therapy practices in human are still facing the challenges of potential safety
and efficacy issues. A number of somatic gene therapy for some lethal diseases have a great achievement both in researches and in clinical practices, most recently, a few of gene therapy programs or drugs have been
approved by FDA.
Germline gene therapy results in genetic permanent changes inherited the next generations which have
potential to offering a permanent therapeutic effect for these families with genetic diseases. The one way to
manipulating germline therapy is to clean the defected gene in the male sperm cells with a genetic disease.
In brief, a healthy gene is replaced to the defective one in each sperm-producing cell, and these replaced
sperm-producing cells are screened and put into the testes for maturation and producing healthy sperm,
finally in the laboratory, these healthy sperm was tested and used for fertilization. By this way, it is possible
to eliminate the genetic disease permanently from a particular family. Also a defective gene can be modified
in the female oocytes to produce healthy eggs for fertilization. Masahito Tachibana, et al. [55] investigated
the feasibility of mtDNA replacement in human oocytes by spindle transfer, it shows spindle transfer
embryos are capable of developing to blastocysts, although some oocytes displayed abnormal fertilization.
The germline gene therapy has a potential benefit to permanently genetic modification of inherited lethal
diseases, however, human germline gene therapy intervention is extremely difficult to study and evaluate
experimentally, its medical perspective is limited due to the safety and ethical considerations.
Embryonic stem (ES) cells or induced pluripotent stem (iPS) cells also offer great potential for cell based gene therapy against genetic disorders, however, ES cells for gene therapy may need a patient-specific ES cells to eliminate or decrease the host immunorejection of cell transplantation, many ethical concerns are also involved in the clinical practices. As an option, iPS cell can be generated from an individual tissue cell with genetic manipulation through defined factors [56]. With iPS cell mediated gene therapy, it can contribute to genetic modification of the specialized function of any tissues and provide a genetic background match with the patient to decrease the likelihood of immunorejection. A genetic disorder, human DMD was treated via gene therapy with patient-derived iPS in a mouse model, which demonstrated chimeric mice with genetic corrected dystrophin expression in all examined tissues [57].
Due to ethnical considerations of germline gene therapy, most of diseases involved in genetic corrections are
employing the strategy of somatic gene therapy which only affects the target cells. Somatic gene therapy can
manipulate modified cells outside and then transplant back into body or the specific tissues (ex vivo), such
as mesenchymal stem (MSC) cells, hematopoietic stem cell (HSC) and tissue-specific stem cells mediated
gene therapy, etc. Bone marrow cells and peripheral blood lymphocytes mediated retroviral vectors gene
therapy (ex vivo) was used for treatment of adenosine deaminase (ADA) deficiency in two patients, the
result demonstrated the transferred ADA gene can express in T and B lymphocytes, marrow cells and
granulocytes which resulted into normalization of the immune repertoire and restoration of cellular and
humoral immunity after 2 years of treatment [7]. Also, HSC mediated gene therapy for two patients with
adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) showed engraftment of
engineered HSCs with differentiation into multiple lineages, which result in increased lymphocyte counts,
improved immune functions and lower toxic metabolites [6]. Subsequently, hematopoietic stem/progenitor cells mediated lentiviral gene therapy for Wiskott-Aldrich syndrome (WAS) showed a positive therapeutic
efficacy in three patients [58]. Currently, HSC mediated gene therapy is widely acceptable in the research
and clinical application, although it provides an innovative treatment option for hematological disorders,
long-term side effects are hard to predict and clinical experience remains limited.
Also gene therapy can be manipulated through directly transferring genetic agents into cells inside the patient’s body (in vivo). Adenovirus-mediated herpes simplex virus thymidine kinase (HSV-tk) can treat brain tumor, gliomas by in vivo gene therapy [59]. With rat carotid artery balloon injury model, researches demonstrated endothelial cell nitric oxide synthase (ec-NOS) in the vessel wall was restored by the Sendai virus/liposome in vivo gene transfer, which shows potential to treatment of neointimal hyperplasia with in vivo ec-NOS gene transfer [60].
Prospect and Challenges of Gene Therapy
Most recently, development of CRISPR-Cas9 gene editing technology offers vast potential to manipulate
gene therapy either in local somatic gene correction or in germline modification, which make the process of
gene manipulation be simple, specific, high efficient and accurate in clinical application. Currently, although
scientific and safety challenges do remain and emerge to be resolved, such as, improvement of gene vector
delivery and gene editing efficiency, control of immune responses and potential adverse effects, evaluation
of germline gene therapy intervention, decrease of off-target effects, etc., gene therapy has made a great
progress from researches in model animals and clinical trails to produce measurable benefits in the clinic
and commercialization. In 2017, The FDA in Unite State approved the first three gene therapy products,
Kymriah for treatment of ALL, GALGT2 gene therapy for treatment of DMD, and Luxturna for treatment
of retinal dystrophy. Given the rapid evolution and technological breakthrough in this field, it is reasonable
that more and more gene therapy products and programs would be approved and commercialized.
Acknowledgments
This work was supported by Beyond Biotech, LLC. We appreciate Prof. Guangping Gao in Horae Gene
Therapy Center at University of Massachusetts Medical School and Dr. Meiyu Xu in UCB, Inc. for offering
the precious reviews and suggestions.
Bibliography
Hi!
We're here to answer your questions!
Send us a message via Whatsapp, and we'll reply the moment we're available!